GlyTherix
GlyTherix is a clinical-stage targeted radiotherapy company developing a first-in-class therapeutic antibody to treat solid tumors expressing Glypican-1 (GPC-1), a cell surface target that occurs within many solid tumors including prostate, bladder & pancreatic cancers.